Risk Factors and Prevention of Stomach Cancer, Excluding <i>Helicobacter pylori</i>

Seung-Woo Lee

doi:10.7704/kjhugr.2024.0035

Korean J Helicobacter Up Gastrointest Res > Volume 24(3); 2024 > Article

Lee: Risk Factors and Prevention of Stomach Cancer, Excluding Helicobacter pylori

Review

The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2024;24(3):243-251.

Published online: September 9, 2024

DOI: https://doi.org/10.7704/kjhugr.2024.0035

Risk Factors and Prevention of Stomach Cancer, Excluding Helicobacter pylori

Seung-Woo Lee

Division of Gastroenterology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea

Corresponding author Seung-Woo Lee, MD, PhD Division of Gastroenterology, Department of Internal Medicine, Daejeon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 64 Daeheung-ro, Jung-gu, Daejeon 34943, Korea E-mail: leeseungw0@catholic.ac.kr

Received May 13, 2024; Revised June 3, 2024; Accepted June 17, 2024;

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Gastric cancer is a significant health problem owing to its high incidence and mortality rate. The risk factors for gastric cancer include both uncontrollable (e.g., age, sex, and genetic predisposition) and controllable factors (e.g., Helicobacter pylori infection, smoking, alcohol consumption, obesity, and high-salt diets). Although treatment of H. pylori infections has been implemented as a primary preventive measure, the risk of gastric cancer may persist, highlighting the need for additional preventive measures. This review discusses various risks and protective factors associated with gastric cancer, studies conducted on these factors, and chemoprevention. Smoking is a risk factor for this disease; thus, is not recommended and current smokers are encouraged to quit because cessation can reduce the risk of gastric cancer. Excessive alcohol intake has been reported to increase the risk of gastric cancer as has the consumption of high-salt foods that can damage the gastric mucosa. Additionally, increasing the intake of fruits and vegetables, known for their protective effects against gastric cancer, can aid in its prevention. Studies on chemopreventive agents, including nonsteroidal anti-inflammatory drugs (e.g., aspirin), statins, and metformin, have been reported; however, evidence of their effectiveness remains insufficient to recommend these agents as preventive treatments. Additional well-planned studies on preventive medications and dietary approaches are necessary.

Key words: Gastric neoplasm; Prevention; Risk factor; Diet modification

INTRODUCTION

Gastric cancer is the fifth most common cancer worldwide, and the fourth leading cause of cancer-related deaths, making it a significant health concern [1]. According to data based on cancer-related information in Korea from 2012 to 2019 and published in 2024, gastric cancer has the highest incidence among men (16.1%) and the fourth highest among women (7.8%). In terms of cancer specific mortality, it ranked third for men (9.6%) and fourth for women (9.1%) [2]. However, the incidence and mortality rates of gastric cancer in Korea are gradually decreasing, with increasing trend in the proportion of localized cancers and a decreasing trend in the proportion of regional and distant cancers. Additionally, the 5-year survival rate has significantly improved from 55.7% (1999–2005) to 77% (2013– 2019) [3]. Moreover, Korea has the highest gastric cancer survival rate globally [4], which is attributed to early detection through the national cancer screening program and good accessibility to medical services. The incidence of gastric cancer is also declining worldwide due to the decreased prevalence of Helicobacter pylori, improved socioeconomic conditions, advancements in food preservation, and increased availability of clean water and sanitation facilities [5].

Gastric cancer consists of two anatomical subtypes: cardia and non-cardia gastric cancer, each with a different epidemiology and risk factors [6]. Histologically, it can be divided into two types: intestinal and diffuse. Diffuse-type gastric cancer is thought to occur because of genetic mutations affecting pathways associated with cell-extracellular matrix interactions, whereas the more common intestinal-type gastric cancer can be caused by factors such as H. pylori infections that induce chronic inflammatory damage to the gastric mucosa [7-10].

The primary risk factor for gastric cancer is an H. pylori infection, the treatment of which is known to reduce the incidence of gastric cancer [11]. However, since the risk of gastric cancer persists even after eradication therapy [12], exploring other risk factors and discussing methods that help prevent gastric cancer is necessary. This article describes the primary prevention strategies for gastric cancer other than H. pylori eradication therapy.

RISK FACTORS FOR STOMACH CANCER

Various risk factors are associated with the development of gastric cancer. Some risk factors, such as age, sex, race, family history, and genetics, cannot be modified. However, there are modifiable factors, including H. pylori infection; alcohol consumption; smoking; obesity; lifestyle habits; and exposure to chemicals, radiation, or viruses [13]. The following overview summarizes the major risk factors for gastric cancer and their association with its occurrence.

Age and sex

Like other cancers, the incidence of gastric cancer increases with age; it is also two to three times more common in men than in women [13,14]. In men over 65 years of age, intestinal-type gastric cancer occurs more frequently than the diffuse type, whereas the diffuse type is more common in younger individuals and women [7,15]. According to a 2020 study, cardia gastric cancer occurs approximately four times more frequently in men than in women, with the male-to-female ratio peaking between the ages of 50 years and 69 years. This sex difference in incidence may be due to the protective effect of female hormones against cardia gastric cancer as well as factors such as abdominal obesity (a male-pattern fat distribution) or smoking [16].

Family history and genetics

Having a first-degree relative with gastric cancer is known to increase the risk of gastric cancer by about 2.5 times [17]. Whereas most cases of gastric cancer occur sporadically, about 10% show familial clustering [18]. In high-incidence regions, familial clustering may be due to shared risk factors such as H. pylori infections [19]. In low-incidence areas, genetic factors may play a role, although globally, only 1%–3% of cases are known to be truly hereditary. The three genetic syndromes primarily associated with gastric cancer are hereditary diffuse gastric cancer (HDGC), gastric adenocarcinoma and proximal polyposis of the stomach, and familial intestinal gastric cancer [18].

HDGC syndrome is caused by cadherin 1 (CDH1) germline mutations, leading to an E-cadherin protein deficiency that results in the development and invasion of signet ring cell carcinoma [20]. For most HDGC patients, the cumulative incidence of gastric cancer by 80 years of age is 70% for men and 56% for women. Women also have a 42% risk of lobular breast cancer [8]. According to the 2015 International Gastric Cancer Linkage Consortium guidelines, CDH1 genetic testing should be performed if any of the following three conditions are met: 1) Families including two or more individuals with gastric cancer at any age, with one confirmed to be diffuse gastric cancer; 2) Individuals diagnosed with diffuse gastric cancer before the age of 40; and 3) Families with individuals diagnosed with both diffuse gastric cancer and lobular breast cancer (one diagnosis before 50 years of age) [21].

Prophylactic total gastrectomy is a potentially life-saving surgery for asymptomatic carriers of the CDH1 mutations. This is because endoscopic surveillance has been reported to be ineffective in HDGC cases, as early HDGC lesions are generally not visible and lie beneath the normal mucosa [22].

According to the 2020 HDGC guidelines, carriers of the CDH1 mutation with a confirmed family history of HDGC should consider prophylactic total gastrectomy, regardless of endoscopic findings. Surgery is typically recommended in early adulthood, between the ages of 20 years and 30 years. For older individuals, prophylactic total gastrectomy is not recommended for patients over 70 years of age, unless there are special circumstances. This is due to the longer recovery periods and increased surgery-related risks in older patients. Those who refuse or wish to delay surgery are advised to undergo annual endoscopic examinations by experienced endoscopists knowledgeable about HDGC; treatment of H. pylori infection is also recommended, if present [23]. A case report from Japan described a patient with HDGC where signet ring cell carcinoma, which had not been visible during endoscopy, was found in seven locations after prophylactic total gastrectomy [24].

Cigarette smoking

Smoking is a significant risk factor for gastric cancer, with studies reporting that cigarette smoke condensate has a carcinogenic effect on the gastric mucosa [25]. Moreover, tobacco products contain more than 70 human carcinogens, including polycyclic aromatic hydrocarbons, nitrosamines, and other N-nitroso compounds [26]. These carcinogens can form covalent bonds with deoxyribonucleic acid (DNA), altering normal DNA function and ultimately leading to the development of gastric cancer [27].

A meta-analysis of 32 research papers published in 2008 showed that current smokers have an increased risk of gastric cancer compared with nonsmokers, including a higher risk of both cardia (relative risk [RR], 1.87; 95% confidence interval [CI], 1.31–2.67) and non-cardia cancer (RR, 1.6; 95% CI, 1.41– 1.8) [28]. Regarding differences in cell differentiation types, a 2002 study reported that both former smokers (adjusted rate ratio, 2.0; 95% CI, 1.1–3.7) and current smokers (adjusted rate ratio, 2.1; 95% CI, 1.2–3.6) had higher risks of intestinal-type gastric cancer than nonsmokers, but there was no association with diffuse-type gastric cancer [29].

According to the Stomach Cancer Pooling Project (StoP Project), published in 2018, current smokers have a higher risk of developing gastric cancer than former smokers. This risk increases with the number of cigarettes smoked per day (≥20 cigarettes per day: odds ratio [OR], 1.32; 95% CI, 1.10–1.58) and the duration of regular smoking (≥40 years: OR, 1.33; 95% CI, 1.14–1.54). The risk of gastric cancer decreased with an increasing number of years since quitting; former smokers who had quit for more than 10 years showed no difference in gastric cancer risk compared with nonsmokers [30].

The most recent meta-analysis, published in 2024, analyzed 205 studies and found that current smokers had a higher probability of developing gastric cancer (RR, 1.53; 95% CI, 1.44– 1.62) compared with never-smokers, whereas former smokers had a somewhat lower risk (RR, 1.3; 95% CI, 1.23–1.37). Current smokers had a higher risk of cardia cancer (RR, 2.08; 95% CI, 1.66–2.61) and of distal cancer (RR, 1.48; 95% CI, 1.33–1.66) compared with non-smokers. The risk of gastric cancer increased with smoking intensity of up to 20 cigarettes per day, with no further increase observed with higher smoking intensities. The risk of gastric cancer increased linearly with the duration of smoking and decreased significantly with increasing time since quitting [31].

Alcohol consumption

Alcohol can promote the absorption and metabolism of carcinogens; form chemical bonds with membrane phospholipids to disrupt tight junction structures; contribute to the regulation of genes related to cancer proliferation, invasion, and metastasis; and generate reactive oxygen species that contribute to the metabolic activation of chemical carcinogens and activate signaling molecules involved in inflammation, metastasis, and angiogenesis. Additionally, alcohol consumption can cause folate deficiency, leading to abnormal DNA methylation, which can contribute to the development of gastric cancer [32].

A 2017 meta-analysis examined the differences in alcoholrelated risk according to the anatomical subtypes of gastric cancer. Heavy alcohol consumption was significantly associated (although the difference was not large [RR, 1.16; 95% CI, 0.98–1.39]) with the risk of non-cardia gastric cancer (RR, 1.19; 95% CI, 1.01–1.40) but not with the risk of cardia gastric cancer [33].

The 2017 StoP Project, which analyzed pooled data from 20 studies (9669 cases and 25336 controls) in Europe, Asia, and North America, found that heavy drinkers (defined as consuming 48–72 g of alcohol per day) had an OR of 1.26 (95% CI, 1.08–1.48) for developing gastric cancer, whereas very heavy drinkers (consuming >72 g per day) had an OR of 1.48 (95% CI, 1.29–1.70). Subgroup analysis revealed that consuming over 48 g of alcohol per day was more strongly associated with the risk of cardia cancer (OR, 1.61; 95% CI, 1.11–2.34) than noncardia cancer (OR, 1.28; 95% CI, 1.13–1.45) and showed a stronger association with intestinal-type gastric cancer (OR, 1.54; 95% CI, 1.20–1.97) than the diffuse type (OR, 1.29; 95% CI, 1.16–2.00). This study also reported that alcohol consumption of <48 g per day did not increase the risk of gastric cancer [34].

A cohort study from 2018 reported no relationship between alcohol consumption and gastric cancer, but suggesting that drinking ≤13–14 g of alcohol per day may have a protective effect against gastric cancer [35].

A meta-analysis of 81 epidemiological studies, published in 2021, reported a consistent association between drinking and gastric cancer, with alcohol consumers having a higher risk of gastric cancer than non-drinkers (OR, 1.2; 95% CI, 1.12–1.27). The risk, according to alcohol consumption, was negligible at 10 g per day (OR, 1.01; 95% CI, 0.94–1.09), slight at 50 g per day (OR, 1.14; 95% CI, 1.06–1.21), and high at 100 g per day (OR, 1.32; 95% CI, 1.18–1.48). When examining gastric cancer by location, cardia gastric cancer (OR, 1.18; 95% CI, 1.03–1.35) showed a stronger association than non-cardia gastric cancer with alcohol consumption (OR, 0.93; 95% CI, 0.76–1.13) [36].

Obesity

The incidence and prevalence of obesity have been increasing in recent years [37]. Obesity-related accumulation of adipose tissue in various organs can lead to abnormal cellular functions, potentially causing chronic diseases such as cancer. Excessive accumulation of abdominal fat is particularly associated with insulin resistance [38]. Since insulin and insulin-like growth factor 1 (IGF-I) play crucial roles in cell proliferation, changes in insulin resistance can lead to impaired apoptosis and tumor development. Additionally, cytokines, such as leptin and adiponectin, produced in response to obesity can cause inflammation and promote cancer development [39,40].

A meta-analysis published in 2009, including data from 10 cohort studies, found that being overweight (body mass index [BMI] ≥25 kg/m²) was associated with an increased risk of gastric cancer in non-Asians (OR, 1.24; 95% CI, 1.14–1.36) but not in Asians (OR, 1.17; 95% CI, 0.88–1.56) [41]. A meta-analysis of 24 prospective studies published before 2012 showed that being overweight (BMI, 25–29.9 kg/m²) or obese (BMI ≥30 kg/m²) was not associated with gastric cancer, overall. However, when gastric cancer was classified according to location, obesity was associated with an increased risk of cardia cancer. The summary relative risk (SRR) for cardia cancer was 1.21 (95% CI, 1.03–1.42) for overweight individuals and 1.82 (95% CI, 1.32–2.49) for obese individuals; there was no association with non-cardia cancer risk (overweight SRR, 0.93; 95% CI, 0.82–1.05 and obese SRR, 1.00; 95% CI, 0.87–1.15) [42].

A 2022 study (n=538835) published by the Asian Cohort Consortium examined the association between BMI and gastric cancer in 8997 gastric cancer patients and, contrary to previous studies, found that both underweight and obesity were associated (a U-shaped association) with gastric cancer risk compared with the normal BMI group (hazard ratio [HR], 1.15; 95% CI, 1.05–1.25 and HR, 1.12; 95% CI, 1.03–1.22, for underweight and obese individuals, respectively). Subtype analysis revealed that being underweight or obese was associated with non-cardia, intestinal-type gastric cancer, and cancer occurring in those over 70 years old. However, this study was limited by its focus on Asian populations, with fewer overweight or obese individuals with predominantly non-cardia cancers, making it difficult to confirm the association between obesity and cardia cancer [43].

A meta-analysis of the association between weight and gastric cancer, published in 2023, included 14020031 participants from 13 studies. The pooled RR for gastric cancer was 1.124 (95% CI, 0.968–1.304; heterogeneity statistic [I²], 89.08%) in the underweight group, 1.155 (95% CI, 1.051–1.270; I², 95.18%) in the overweight group, and 1.218 (95% CI, 1.070–1.386; I², 97.65%) in the obese group, indicating that being overweight or obese increased the risk of gastric cancer. Subgroup analysis showed that the association between being overweight/obese and gastric cancer was stronger in non-Asians and women than in Asians and men, with no significant difference between cardia and non-cardia cancers. The relatively minor role of BMI as a risk factor for gastric cancer among Asians may be attributed to other factors, such as H. pylori infection, genetic factors, high-sodium diets, and other environmental factors that play more prominent roles in gastric cancer development in this population [38].

High-salt diet

High salt intake has been reported to increase H. pylori colonization, exacerbate gastritis, and potentially accelerate H. pylori-associated carcinogenesis [44]. Furthermore, excessive salt consumption can damage the gastric mucosa and promote gastric cancer development by increasing DNA synthesis and cell proliferation [45].

A meta-analysis of data from seven cohort studies in 2012 showed that a high-salt diet increases the risk of gastric cancer compared with a low-salt diet (RR, 1.6; 95% CI, 1.41–1.8) [46]. A 2015 study on the relationship between dietary factors and gastric cancer reported that increasing salt intake by 5 g per day was associated with a 12% increase in gastric cancer risk [47].

A meta-analysis of data from 25 case-control studies in the 2022 StoP Project revealed that individuals who prefer salty foods have a higher risk of gastric cancer compared with those preferring tasteless foods (OR, 1.59; 95% CI, 1.25–2.03). Individuals in the highest tertile of the highly salted food consumption group also had a higher risk of gastric cancer (OR, 1.24; 95% CI, 1.01–1.51) than those in the lowest tertile. These associations were consistently observed regardless of H. pylori infection status [48].

Another meta-analysis in 2022, which included 38 case-control studies, demonstrated a significant association between high salt intake and gastric cancer (OR, 1.55; 95% CI, 1.45–1.64; p<0.001) [49].

PROTECTIVE FACTORS FOR STOMACH CANCER

Fruit and vegetable consumption

Fruits and vegetables are rich in antioxidants and anticancer substances, such as vitamin C, carotenoids, and catechins. These antioxidant properties can potentially eliminate free radicals that may cause mutations, induce the production of detoxifying enzymes, and counteract DNA damage caused by H. pylori [50-52].

According to a meta-analysis published in 2007, high consumption of fruits and vegetables is associated with a reduced risk of gastric cancer, with a pronounced association with intestinal-type gastric cancer [53]. A 2014 meta-analysis study that included over 2.4 million individuals (6600 gastric cancer patients) followed for more than 10 years showed that fruit consumption was associated with gastric cancer risk reduction (SRR, 0.9; 95% CI, 0.83–0.98). However, this study found that vegetable consumption did not reduce the risk (SRR, 0.96; 95% CI, 0.88–1.06) [54].

The meta-analysis results from the StoP Project published in 2020 reported data showing that people in the highest tertile of fruit consumption (OR, 0.76; 95% CI, 0.64–0.90), vegetable consumption (OR, 0.68; 95% CI, 0.56–0.84), and combined fruit and vegetable intake (OR, 0.61; 95% CI, 0.49–0.75) had significantly reduced risks of gastric cancer development compared with those in the lowest tertile [55].

A 2023 meta-analysis study reported that total fruit intake (RR, 0.87; 95% CI, 0.8–0.94) and total fruit and vegetable intake (RR, 0.75; 95% CI, 0.61–0.93) were associated with a 13% and 25% lower risk of gastric cancer, respectively. The study also found that for every 100 g increase in daily total fruit intake (pooled RR, 0.95; 95% CI, 0.90–0.99) and every 200 g increase in daily total fruit and vegetable intake (pooled RR, 0.94; 95% CI, 0.88–0.99), the risk of gastric cancer was reduced by 5% and 6%, respectively [56].

Other dietary factors

Meta-analyses have been conducted on various dietary factors, in addition to fruits and vegetables. Notably, the ongoing StoP Project (established in 2012) investigating lifestyle, environmental, and genetic determinants of gastric cancer [57] has been sequentially publishing research results. Recent studies have identified excessive alcohol consumption, total meat intake, red meat, processed meat, and salt intake, as risk factors for gastric cancer. In contrast, fruits, vegetables, mushrooms, green tea, polyphenol, and vitamin C intake have been shown to reduce the risk [58,59].

CHEMOPREVENTION

Nonsteroidal anti-inflammatory drugs

Aspirin is known to reduce the risk of colorectal, breast, and lung cancers, and several studies have reported its effects on gastric cancer. Nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin, can have antitumor growth effects through cyclooxygenase-2 (COX-2) blockade, inhibition of angiogenesis, and upregulation of mediators (such as caspase-3 activation) that induce apoptosis [12]. Additionally, aspirin and nonaspirin NSAIDs can exert chemopreventive effects through COX-independent pathways, including nuclear factor-κB, activated protein 1, Wnt-β-catenin, and extracellular signal-regulated kinase [12].

A 2009 cohort study in the United States, involving 643 cancer patients and 168649 cancer-free individuals, found that regular aspirin use was associated with a reduced risk of distal gastric cancer (HR, 0.73; 95% CI, 0.61–0.89; p_trend=0.009). However, the use of non-aspirin NSAIDs was not associated with a reduced risk of distal gastric cancer (HR, 1.00; 95% CI, 0.81– 1.24; p_trend=0.99). The inverse relationship between regular aspirin use and gastric cancer development was observed only in intestinal-type distal gastric adenocarcinoma (HR, 0.66; 95% CI, 0.47–0.95; p_trend=0.01) and not in diffuse-type distal gastric adenocarcinoma (HR, 0.92; 95% CI, 0.53–1.60; p_trend=0.45) [60].

A 2017 study showed that NSAIDs reduced the risk of gastric cancer for all types of NSAIDs (RR, 0.78; 95% CI, 0.72– 0.85), aspirin (RR, 0.70; 95% CI, 0.62–0.80), and for non-aspirin NSAIDs (RR, 0.86; 95% CI, 0.80–0.94), with particular effectiveness for reducing the risk of non-cardia gastric cancer. A dose-response analysis showed that for every 2-year increase in the duration of NSAID and aspirin use, the risk of gastric cancer decreased by 11% and 5%, respectively [61].

A 2020 meta-analysis of the association between aspirin use and gastric cancer used fixed- and random-effects models; the pooled risk ratios for gastric cancer incidence were 0.890 (95% CI, 0.871–0.909) and 0.826 (95% CI, 0.740–0.922), respectively, indicating an association with reduced gastric cancer occurrence. Preventive effects were observed after weekly or daily aspirin use rather than with intermittent or monthly use. A subgroup analysis described the preventive effects of aspirin use within 5 years and its effectiveness in reducing non-cardia gastric cancer [62].

Another 2020 meta-analysis analyzed the effect of aspirin in reducing the risk of gastric cancer. Low-dose aspirin showed slightly greater risk reduction (OR, 0.80; 95% CI, 0.59–1.09) than high-dose aspirin (OR, 1.08; 95% CI, 0.77–1.52). The protective effect associated with aspirin use for more than five years (OR, 0.67; 95% CI, 0.34–1.31) was greater than that for aspirin use for less than 5 years (OR, 1.01; 95% CI, 0.72–1.43), suggesting that low-dose aspirin use for more than five years could reduce gastric cancer risk [63].

To date, the reported risk-reduction effects of NSAIDs on gastric cancer have generally shown better results for aspirin than for other NSAIDs, with long-term use showing risk-reduction effects associated with non-cardia gastric cancer. However, well-designed randomized controlled trials are lacking, and the type, dosage, duration, and frequency of drug use have not been clearly defined. Moreover, the risk of side effects (e.g., bleeding) associated with the use of these drugs must be considered. Therefore, recommending aspirin use for the prevention of gastric cancer is currently difficult.

Statins

Statins are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductase, a class of drugs that lowers serum lipid levels. Various metabolites of cholesterol metabolism are involved in the carcinogenesis process [64]. The inhibition of HMG-CoA reductase leads to a decrease in mevalonic acid, which downregulates mediators essential for the downstream regulation of G-protein-coupled receptors in various pathways, notably the Ras signaling pathway that promotes cell growth and survival in various cancer cells. Statins are also described as having antiangiogenic, antiproliferative, and proapoptotic effects, and are known to inhibit the growth of several tumor types, including gastric cancer, in vitro and in animal models [64,65].

A 2013 meta-analysis found an association between statin use and a reduced risk of gastric cancer (adjusted OR, 0.84; 95% CI, 0.78–0.90). This association was observed in both Asian (adjusted OR, 0.68; 95% CI, 0.53–0.87) and Western populations (adjusted OR, 0.86; 95% CI, 0.79–0.93). Long-term (≥2 years) statin use (OR, 0.35; 95% CI, 0.16–0.76) showed an increased protective effect against gastric cancer compared with short-term use (<2 years; OR, 0.73; 95% CI, 0.51–1.05) [66].

A 2013 meta-analysis of data from 26 randomized controlled trials showed that statin use is associated with a 27% reduction in gastric cancer risk (RR, 0.73; 95% CI, 0.58–0.93). However, this protective effect decreased, but remained significant, when studies focusing solely on patients with diabetes were excluded (RR, 0.85; 95% CI, 0.80–0.91) [67].

A 2021 retrospective study in Korea showed that statins reduced the risk of metachronous gastric cancer after endoscopic resection of early gastric cancer [68].

A 2022 meta-analysis of 20 case-control and randomized controlled studies found that statin use was associated with a reduction in gastric cancer risk (adjusted RR, 0.72; 95% CI, 0.64–0.81; p<0.001). When analyzed by patient ethnicity, the effect of statin use on gastric cancer risk showed a more protective effect in Asians than in Westerners (Asian RR, 0.62; 95% CI, 0.53–0.73 vs. Western RR, 0.88; 95% CI, 0.79–0.99) [69].

A meta-analysis published in 2023, analyzing 23 studies, found that patients in the statin use group had a significantly lower risk of gastric cancer than those in the non-statin use group (OR/RR, 0.74; 95% CI, 0.67–0.80; p<0.001). The study also showed that the statin use group had significantly lower all-cause mortality and gastric cancer-specific mortality than the non-statin use group (all-cause mortality: RR, 0.70; 95% CI, 0.52–0.95; p=0.021; cancer-specific mortality: RR, 0.70; 95% CI, 0.58–0.84; p<0.001) [70].

Metformin

Diabetes is a known risk factor for gastric cancer [71]. The anticancer effect of metformin, which is primarily used in the treatment of diabetes, is mediated through various pathways. Metformin acts as an insulin sensitizer, reducing the production of insulin and IGF. This can inhibit the IGF signaling pathway that promotes the proliferation of cancer cells expressing IGF receptors [72]. Secondly, the activation of adenosine monophosphate-activated protein kinase and the subsequent inhibition of the mammalian target of rapamycin complex 1 signaling pathway and survivin (a protein that inhibits cancer cell apoptosis) are known to induce cancer cell death [73-76].

Several clinical studies have reported an association between metformin use and gastric cancer. In a 2014 study by Kim et al. [77], patients who did not use insulin but who used metformin for more than 3 years showed a 43% reduction in gastric cancer risk, whereas there was no difference in gastric cancer incidences between patients using or not using metformin among individuals using insulin. In 2016, Lee et al. [78] reported that among gastrectomy patients with diabetes, the use of metformin for more than 6 months reduced cancer-related mortality and recurrence rates. A 2017 meta-analysis showed that metformin treatment in patients with type 2 diabetes lowered the risk of gastric cancer development (HR, 0.763; 95% CI, 0.642– 0.905) [79]. A 2019 study from Taiwan reported that metformin use in patients with diabetes, after H. pylori eradication, demonstrated a reduced risk (reduction of approximately 51%) of gastric cancer, with a trend related to dose and duration of use [80]. A meta-analysis published in 2020 analyzed 11 cohort studies and reported that metformin use reduced gastric cancer incidence by 21% in patients with type 2 diabetes. However, this effect, observed in Asians, was not observed in Western patients [81].

A 2023 study analyzing the cancer prevention effects of metformin on various cancer types showed that metformin reduced the incidence of liver, pancreatic, colorectal, and gastric cancers (OR, 0.72; 95% CI, 0.26–1.99) [82]. Although numerous studies have reported the preventive effect of metformin on gastric cancer, there have also been studies showing no effect [83-86]. Additionally, as most of these are observational studies, the results may be biased due to unadjusted confounding factors [87].

PRIMARY PREVENTION STRATEGIES FOR GASTRIC CANCER

For the primary prevention of intestinal-type gastric cancer, there is sufficient evidence to support the benefits of H. pylori eradication before the development of advanced precancerous mucosal changes [12], and this method is currently being used in clinical practice. In addition to H. pylori eradication, numerous studies have been conducted on medications, such as NSAIDs, statins, and metformin, with some studies showing a reduction in gastric cancer risk. However, because most of these were observational studies, there is insufficient evidence to recommend them for preventive purposes [64].

Another preventive method involves the modification of lifestyle habits to avoid known risk factors, such as smoking and alcohol consumption. The risk of gastric cancer increases with the amount of tobacco smoked and decreases after a long period following smoking cessation [31]. Therefore, active smoking cessation education is needed. Although the relationship between consuming small amounts of alcohol and gastric cancer development is not clear, most studies report that excessive drinking is a risk factor; therefore, heavy drinking should also be avoided.

Another method of reducing the risk of gastric cancer involves dietary modifications. A high-salt diet can promote H. pylori colonization and damage the gastric mucosa, potentially promoting gastric cancer development. Therefore, reducing salt intake and consuming sufficient quantities of fruits and vegetables, which have protective effects, should also be recommended. A 2020 American Cancer Society paper regarding diet and physical activity for cancer prevention recommended weight control, regular moderate or higher intensity physical activity, and limited consumption of processed or grilled meats [88].

Preventive total gastrectomy may be helpful for individuals with HDGC. Therefore, the family history of patients with diffuse gastric cancer needs to be closely examined.

CONCLUSIONS

Gastric cancer is a disease with high incidence and mortality rates. However, its prevalence in Korea warrants special attention. There are several risk and protective factors associated with this type of cancer, necessitating an understanding of these factors and the methods used to mitigate the role of these risk factors. Thus, limiting smoking, alcohol consumption, and salt intake should be encouraged, along with the recommendation to consume adequate amounts of fruits and vegetables.

Although chemoprevention cannot yet be routinely recommended, active health management through medications such as aspirin, metformin, and statins may be necessary when vascular diseases, diabetes, or hyperlipidemia are present.

Future well-designed prospective studies are needed to prove the effectiveness of drugs (beyond the use of drugs for eradicating H. pylori) and dietary factors in preventing gastric cancer and for establishing guidelines for their use.

Notes

Availability of Data and Material

Data sharing is not applicable to this article, as no datasets were generated or analyzed during the study.

Conflicts of Interest

The author has no financial conflicts of interest.

Funding Statement

None

Acknowledgements

None

REFERENCES

1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209–249.

2. Choi DW, Guk M, Kim H, et al. Data resource profile: the cancer public library database in South Korea. Cancer Res Treat 2024;Apr 30 [Epub]. https://doi.org/10.4143/crt.2024.207.

3. Park SH, Kang MJ, Yun EH, Jung KW. Epidemiology of gastric cancer in Korea: trends in incidence and survival based on Korea Central Cancer Registry Data (1999-2019). J Gastric Cancer 2022;22:160–168.

4. Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018;391:1023–1075.

5. GBD 2017 Stomach Cancer Collaborators. The global, regional, and national burden of stomach cancer in 195 countries, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol 2020;5:42–54.

6. Karimi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev 2014;23:700–713.

7. Thrift AP, Wenker TN, El-Serag HB. Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention. Nat Rev Clin Oncol 2023;20:338–349.

8. Hansford S, Kaurah P, Li-Chang H, et al. Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond. JAMA Oncol 2015;1:23–32.

9. Correa P, Haenszel W, Cuello C, Tannenbaum S, Archer M. A model for gastric cancer epidemiology. Lancet 1975;306:58–60.

10. Lauren P. The two histological main types of gastric carcinoma: diffuse and so‐called intestinal‐type carcinoma. An attempt at a histoclinical classification. Acta Pathol Microbiol Scand 1965;64:31–49.

11. Ford AC, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis. Gut 2020;69:2113–2121.

12. Shah SC, Peek RM Jr. Chemoprevention against gastric cancer. Gastrointest Endosc Clin N Am 2021;31:519–542.

13. Yang WJ, Zhao HP, Yu Y, et al. Updates on global epidemiology, risk and prognostic factors of gastric cancer. World J Gastroenterol 2023;29:2452–2468.

14. Morgan E, Arnold M, Camargo MC, et al. The current and future incidence and mortality of gastric cancer in 185 countries, 2020-40: a population-based modelling study. EClinicalMedicine 2022;47:101404.

15. van der Kaaij RT, Koemans WJ, van Putten M, et al. A populationbased study on intestinal and diffuse type adenocarcinoma of the oesophagus and stomach in the Netherlands between 1989 and 2015. Eur J Cancer 2020;130:23–31.

16. Yao Q, Qi X, Xie SH. Sex difference in the incidence of cardia and non-cardia gastric cancer in the United States, 1992-2014. BMC Gastroenterol 2020;20:418.

17. Yaghoobi M, McNabb-Baltar J, Bijarchi R, Hunt RH. What is the quantitative risk of gastric cancer in the first-degree relatives of patients? A meta-analysis. World J Gastroenterol 2017;23:2435–2442.

18. Oliveira C, Pinheiro H, Figueiredo J, Seruca R, Carneiro F. Familial gastric cancer: genetic susceptibility, pathology, and implications for management. Lancet Oncol 2015;16:e60–e70.

19. Huang RJ, Laszkowska M, In H, Hwang JH, Epplein M. Controlling gastric cancer in a world of heterogeneous risk. Gastroenterology 2023;164:736–751.

20. Guilford P, Hopkins J, Harraway J, et al. E-cadherin germline mutations in familial gastric cancer. Nature 1998;392:402–405.

21. van der Post RS, Vogelaar IP, Carneiro F, et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet 2015;52:361–374.

22. Corso G, Davis JL, Strong VE. Points to consider regarding prophylactic total gastrectomy in germline CDH1 variant carriers. J Surg Oncol 2024;129:1082–1088.

23. Blair VR, McLeod M, Carneiro F, et al. Hereditary diffuse gastric cancer: updated clinical practice guidelines. Lancet Oncol 2020;21:e386–e397.

24. Inaba Y, Goda K, Kondo M, et al. Hereditary diffuse gastric cancer treated by prophylactic total gastrectomy. Intern Med 2024;63:235–239.

25. Tayler R, Piper DW. The carcinogenic effect of cigarette smoke. The effect of cigarette smoke on human gastric mucosal cells in organ culture. Cancer 1977;39:2520–2523.

26. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Personal habits and indoor combustions. Lyon: International Agency for Research on Cancer, 2012.

27. Dyke GW, Craven JL, Hall R, Garner RC. Smoking-related DNA adducts in human gastric cancers. Int J Cancer 1992;52:847–850.

28. Ladeiras-Lopes R, Pereira AK, Nogueira A, et al. Smoking and gastric cancer: systematic review and meta-analysis of cohort studies. Cancer Causes Control 2008;19:689–701.

29. Sasazuki S, Sasaki S, Tsugane S.; Japan Public Health Center Study Group. Cigarette smoking, alcohol consumption and subsequent gastric cancer risk by subsite and histologic type. Int J Cancer 2002;101:560–566.

30. Praud D, Rota M, Pelucchi C, et al. Cigarette smoking and gastric cancer in the stomach cancer pooling (StoP) project. Eur J Cancer Prev 2018;27:124–133.

31. Rota M, Possenti I, Valsassina V, et al. Dose-response association between cigarette smoking and gastric cancer risk: a systematic review and meta-analysis. Gastric Cancer 2024;27:197–209.

32. Na HK, Lee JY. Molecular basis of alcohol-related gastric and colon cancer. Int J Mol Sci 2017;18:1116.

33. Wang PL, Xiao FT, Gong BC, Liu FN. Alcohol drinking and gastric cancer risk: a meta-analysis of observational studies. Oncotarget 2017;8:99013–99023.

34. Rota M, Pelucchi C, Bertuccio P, et al. Alcohol consumption and gastric cancer risk—a pooled analysis within the StoP project consortium. Int J Cancer 2017;141:1950–1962.

35. Wang S, Freedman ND, Loftfield E, Hua X, Abnet CC. Alcohol consumption and risk of gastric cardia adenocarcinoma and gastric noncardia adenocarcinoma: a 16-year prospective analysis from the NIHAARP diet and health cohort. Int J Cancer 2018;143:2749–2757.

36. Deng W, Jin L, Zhuo H, Vasiliou V, Zhang Y. Alcohol consumption and risk of stomach cancer: a meta-analysis. Chem Biol Interact 2021;336:109365.

37. Liu X, He M, Li Y. Adult obesity diagnostic tool: a narrative review. Medicine (Baltimore) 2024;103:e37946.

38. Azizi N, Zangiabadian M, Seifi G, et al. Gastric cancer risk in association with underweight, overweight, and obesity: a systematic review and meta-analysis. Cancers (Basel) 2023;15:2778.

39. Friedenreich CM, Ryder-Burbidge C, McNeil J. Physical activity, obesity and sedentary behavior in cancer etiology: epidemiologic evidence and biologic mechanisms. Mol Oncol 2021;15:790–800.

40. Cannata D, Fierz Y, Vijayakumar A, LeRoith D. Type 2 diabetes and cancer: what is the connection? Mt Sinai J Med 2010;77:197–213.

41. Yang P, Zhou Y, Chen B, et al. Overweight, obesity and gastric cancer risk: results from a meta-analysis of cohort studies. Eur J Cancer 2009;45:2867–2873.

42. Chen Y, Liu L, Wang X, et al. Body mass index and risk of gastric cancer: a meta-analysis of a population with more than ten million from 24 prospective studies. Cancer Epidemiol Biomarkers Prev 2013;22:1395–1408.

43. Jang J, Lee S, Ko KP, et al. Association between body mass index and risk of gastric cancer by anatomic and histologic subtypes in over 500,000 east and southeast Asian cohort participants. Cancer Epidemiol Biomarkers Prev 2022;31:1727–1734.

44. Fox JG, Dangler CA, Taylor NS, King A, Koh TJ, Wang TC. Highsalt diet induces gastric epithelial hyperplasia and parietal cell loss, and enhances Helicobacter pylori colonization in C57BL/6 mice. Cancer Res 1999;59:4823–4828.

45. Bouras E, Tsilidis KK, Triggi M, Siargkas A, Chourdakis M, Haidich AB. Diet and risk of gastric cancer: an umbrella review. Nutrients 2022;14:1764.

46. D’Elia L, Rossi G, Ippolito R, Cappuccio FP, Strazzullo P. Habitual salt intake and risk of gastric cancer: a meta-analysis of prospective studies. Clin Nutr 2012;31:489–498.

47. Fang X, Wei J, He X, et al. Landscape of dietary factors associated with risk of gastric cancer: a systematic review and dose-response meta-analysis of prospective cohort studies. Eur J Cancer 2015;51:2820–2832.

48. Morais S, Costa A, Albuquerque G, et al. Salt intake and gastric cancer: a pooled analysis within the stomach cancer pooling (StoP) project. Cancer Causes Control 2022;33:779–791.

49. Wu X, Chen L, Cheng J, Qian J, Fang Z, Wu J. Effect of dietary salt intake on risk of gastric cancer: a systematic review and meta-analysis of case-control studies. Nutrients 2022;14:4260.

50. Ferguson LR, Philpott M, Karunasinghe N. Dietary cancer and prevention using antimutagens. Toxicology 2004;198:147–159.

51. McCarty MF. Scavenging of peroxynitrite-derived radicals by flavonoids may support endothelial NO synthase activity, contributing to the vascular protection associated with high fruit and vegetable intakes. Med Hypotheses 2008;70:170–181.

52. Wang YC, Huang KM. In vitro anti-inflammatory effect of apigenin in the Helicobacter pylori-infected gastric adenocarcinoma cells. Food Chem Toxicol 2013;53:376–383.

53. Lunet N, Valbuena C, Vieira AL, et al. Fruit and vegetable consumption and gastric cancer by location and histological type: case-control and meta-analysis. Eur J Cancer Prev 2007;16:312–327.

54. Wang Q, Chen Y, Wang X, Gong G, Li G, Li C. Consumption of fruit, but not vegetables, may reduce risk of gastric cancer: results from a meta-analysis of cohort studies. Eur J Cancer 2014;50:1498–1509.

55. Ferro A, Costa AR, Morais S, et al. Fruits and vegetables intake and gastric cancer risk: a pooled analysis within the stomach cancer pooling project. Int J Cancer 2020;147:3090–3101.

56. Naemi Kermanshahi M, Safaei E, Tutunchi H, et al. Fruit and vegetable intake in relation to gastric cancer risk: a comprehensive and updated systematic review and dose-response meta-analysis of cohort studies. Front Nutr 2023;10:973171.

57. Pelucchi C, Lunet N, Boccia S, et al. The stomach cancer pooling (StoP) project: study design and presentation. Eur J Cancer Prev 2015;24:16–23.

58. Pelucchi C, La Vecchia C, Bonzi R, et al. The global gastric cancer consortium: an update from the stomach cancer pooling (StoP) project. Eur J Cancer Prev 2024;33:433–437.

59. Sassano M, Seyyedsalehi MS, Collatuzzo G, et al. Dietary intake of vitamin C and gastric cancer: a pooled analysis within the stomach cancer pooling (StoP) project. Gastric Cancer 2024;27:461–472.

60. Epplein M, Nomura AM, Wilkens LR, Henderson BE, Kolonel LN. Nonsteroidal antiinflammatory drugs and risk of gastric adenocarcinoma: the multiethnic cohort study. Am J Epidemiol 2009;170:507–514.

61. Huang XZ, Chen Y, Wu J, et al. Aspirin and non-steroidal anti-inflammatory drugs use reduce gastric cancer risk: a dose-response meta-analysis. Oncotarget 2017;8:4781–4795.

62. Niikura R, Hirata Y, Hayakawa Y, Kawahara T, Yamada A, Koike K. Effect of aspirin use on gastric cancer incidence and survival: a systematic review and meta-analysis. JGH Open 2020;4:117–125.

63. Win TT, Aye SN, Lau Chui Fern J, Ong Fei C. Aspirin and reducing risk of gastric cancer: systematic review and meta-analysis of the observational studies. J Gastrointestin Liver Dis 2020;29:191–198.

64. Weltermann T, Schulz C, Macke L. Effect of frequently prescribed drugs on gastric cancer risk. Best Pract Res Clin Gastroenterol 2021;50-51:101741.

65. Vallianou NG, Kostantinou A, Kougias M, Kazazis C. Statins and cancer. Anticancer Agents Med Chem 2014;14:706–712.

66. Singh PP, Singh S. Statins are associated with reduced risk of gastric cancer: a systematic review and meta-analysis. Ann Oncol 2013;24:1721–1730.

67. Wu XD, Zeng K, Xue FQ, Chen JH, Chen YQ. Statins are associated with reduced risk of gastric cancer: a meta-analysis. Eur J Clin Pharmacol 2013;69:1855–1860.

68. Kwon TJ, Kim TJ, Lee H, et al. Statin use decreases the risk of metachronous gastric cancer in patients without Helicobacter pylori infection. Cancers (Basel) 2021;13:1020.

69. Su CH, Islam MM, Jia G, Wu CC. Statins and the risk of gastric cancer: a systematic review and meta-analysis. J Clin Med 2022;11:7180.

70. Chen Y, Zhang J, Zhang Y, Zhu L. Effect of statin use on risk and mortality of gastric cancer: a meta-analysis. Anticancer Drugs 2023;34:901–909.

71. Yoon JM, Son KY, Eom CS, Durrance D, Park SM. Pre-existing diabetes mellitus increases the risk of gastric cancer: a meta-analysis. World J Gastroenterol 2013;19:936–945.

72. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008;8:915–928.

73. Cerda-Opazo P, Valenzuela-Valderrama M, Wichmann I, et al. Inverse expression of survivin and reprimo correlates with poor patient prognosis in gastric cancer. Oncotarget 2018;9:12853–12867.

74. Yusufu A, Tuerdi R, Redati D, Rehemutula A, Zhao ZL, Wang HJ. Expression and clinical correlation of survivin and PTEN in gastric cancer patients. Oncol Lett 2020;20:297.

75. Jalving M, Gietema JA, Lefrandt JD, et al. Metformin: taking away the candy for cancer? Eur J Cancer 2010;46:2369–2380.

76. Han G, Gong H, Wang Y, Guo S, Liu K. AMPK/mTOR-mediated inhibition of survivin partly contributes to metformin-induced apoptosis in human gastric cancer cell. Cancer Biol Ther 2015;16:77–87.

77. Kim YI, Kim SY, Cho SJ, et al. Long-term metformin use reduces gastric cancer risk in type 2 diabetics without insulin treatment: a nationwide cohort study. Aliment Pharmacol Ther 2014;39:854–863.

78. Lee CK, Jung M, Jung I, et al. Cumulative metformin use and its impact on survival in gastric cancer patients after gastrectomy. Ann Surg 2016;263:96–102.

79. Zhou XL, Xue WH, Ding XF, et al. Association between metformin and the risk of gastric cancer in patients with type 2 diabetes mellitus: a meta-analysis of cohort studies. Oncotarget 2017;8:55622–55631.

80. Cheung KS, Chan EW, Wong AYS, et al. Metformin use and gastric cancer risk in diabetic patients after Helicobacter pylori eradication. J Natl Cancer Inst 2019;111:484–489.

81. Shuai Y, Li C, Zhou X. The effect of metformin on gastric cancer in patients with type 2 diabetes: a systematic review and meta-analysis. Clin Transl Oncol 2020;22:1580–1590.

82. Najafi F, Rajati F, Sarokhani D, Bavandpour M, Moradinazar M. The relationship between metformin consumption and cancer risk: an updated umbrella review of systematic reviews and meta-analyses. Int J Prev Med 2023;14:90.

83. Wang YB, Tan LM, Luo L, et al. Immortal time bias exaggerates the effect of metformin on the risk of gastric cancer: a meta-analysis. Pharmacol Res 2021;165:105425.

84. Dulskas A, Patasius A, Linkeviciute-Ulinskiene D, Zabuliene L, Smailyte G. A cohort study of antihyperglycemic medication exposure and survival in patients with gastric cancer. Aging (Albany NY) 2019;11:7197–7205.

85. Zheng J, Xie SH, Santoni G, Lagergren J. Metformin use and risk of gastric adenocarcinoma in a Swedish population-based cohort study. Br J Cancer 2019;121:877–882.

86. MacArthur TA, Harmsen WS, Mandrekar J, Abraha F, Grotz TE. Association of common medications and the risk of early-onset gastric cancer: a population-based matched study. J Cancer Epidemiol 2021;2021:2670502.

87. Cheung KS, Chung KL, Leung WK. Chemopreventive effect of metformin on gastric cancer development. Gut Liver 2022;16:147–156.

88. Rock CL, Thomson C, Gansler T, et al. American Cancer Society guideline for diet and physical activity for cancer prevention. CA Cancer J Clin 2020;70:245–271.